GlassScriptPhysician profile
Jason Cole Fleming
NPI 1053376640
$2,750.47
in general payments reported to CMS, 2019-2025
22 companies · $602 in 2025
The $602 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $625 · 2020: $222 · 2021: $181 · 2022: $247 · 2023: $424 · 2024: $449 · 2025: $602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,475.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $678.98 | 2019-2024 | Xarelto |
| Pfizer INC. | $491.21 | 2019-2025 | |
| Amgen INC. | $270.27 | 2021-2025 | Repatha, Repatha |
| Novo Nordisk INC | $227.50 | 2023-2025 | Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $217.02 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $205.00 | 2019-2025 | Farxiga, Brilinta |
| Merck Sharp & Dohme LLC | $162.75 | 2022-2025 | Verquvo, Capvaxive |
| Lexicon Pharmaceuticals, INC. | $71.22 | 2023-2024 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.90 | 2019-2025 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $57.30 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $36.84 | 2019-2023 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $34.36 | 2019-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $31.46 | 2024 | Arcalyst |
| Inspire Medical Systems, INC. | $28.99 | 2025 | Inspire |
| Amarin Pharma, INC. | $27.70 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $25.20 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Madrigal Pharmaceuticals | $23.93 | 2025 | Rezdiffra |
| Abbott Laboratories | $21.50 | 2024 | Mitraclip |
| Boston Scientific Corporation | $19.83 | 2024 | Watchman Flx |
| Actelion Pharmaceuticals US, INC. | $19.36 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.00 | 2022 | |
| Bridgebio Pharma, INC. | $18.15 | 2025 | Attruby |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Fleming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.